Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,132.05 -7.21 -0.23%
FTSE 100 6,571.82 -12.35 -0.19%
DAX 9,309.06 -8.76 -0.09%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer



 Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast
                                    Cancer

PR Newswire

ROCKVILLE, Md., Oct. 21, 2013

ROCKVILLE, Md., Oct. 21, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ:ENMD),  a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of a variety of cancers, announced today  the presentation of
preclinical data from a study to assess the role of p53 family tumor
suppressors in mediating response to ENMD-2076 in triple-negative breast
cancer (TNBC).  The study was led by Dr. Jennifer R. Diamond of University of
Colorado and the results were presented at the AACR-NCI-EORTC International
Conference being held this week in Boston, Massachusetts.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

Dr. Diamond commented, "The purpose of this study is to utilize TNBC cell line
gene knockdown models to investigate further the role of p53 and p73 in
mediating sensitivity to ENMD-2076.  Data from the study demonstrate that
ENMD-2076 exhibited robust anticancer activity in both p53 mutated and p53
wild type (WT) cell lines. The data also illustrate that both p53 and p73
mediate sensitivity to ENMD-2076 in p53 WT TNBC, while p73 is essential for
induction of senescence following exposure to ENMD-2076, providing support on
the development of predictive biomarkers of response to ENMD-2076 in p53
mutated TNBC currently underway."

Ken K. Ren, Ph.D, EntreMed's Chief Executive Officer, commented, "ENMD-2076 is
currently in Phase 2 clinical trials in patients with TNBC and
advanced/metastatic soft tissue sarcoma, and we expect to begin enrolling in a
multi-center Phase 2 trial in ovarian clear cell carcinomas. We have also been
conducting additional preclinical studies on the drug candidate primarily to
support our clinical trials with better understanding of its mechanism of
actions, predictive biomarkers, and scientific rationale for new clinical
applications. Taken together, we believe they will shed additional light on
more advanced clinical trials and enhance the value of ENMD-2076."  

To view the poster presentation, visit the Company's website at
http://www.entremed.com.

About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a
unique kinase selectivity profile and multiple mechanisms of action. 
ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine
kinase targets in addition to the Aurora A kinase.  Aurora kinases are key
regulators of mitosis (cell division), and are often over-expressed in human
cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have
been shown to play important roles in the pathology of several cancers. 
ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid
tumor cancers, leukemia, multiple myeloma, and is currently completing a Phase
2 trial for ovarian cancer.  EntreMed is currently conducting a Phase 2 study
of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in
advanced/metastatic soft tissue sarcoma, and expecting to initiate a Phase 2
study in ovarian clear cell carcinoma.  ENMD-2076 has received orphan drug
designation from the FDA for the treatment of ovarian cancer, multiple myeloma
and acute myeloid leukemia.

About EntreMed
EntreMed is a clinical-stage pharmaceutical company employing a drug
development strategy primarily in the United States and China to develop
targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a
selective angiogenic kinase inhibitor, has completed several Phase 1 studies
in solid tumors, multiple myeloma, and leukemia, and is currently completing a
multi-center Phase 2 study in ovarian cancer.  EntreMed is currently
conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer, a
Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma, and is
expecting to initiate a Phase 2 study in ovarian clear cell carcinoma.  The
Company is headquartered in Rockville, Maryland and has a wholly-owned
subsidiary in Beijing, China.  Additional information about EntreMed is
available on the Company's web site at www.entremed.com and in various filings
with the Securities and Exchange Commission (the SEC).

Forward Looking Statements           
This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act with respect to the outlook for
expectations for future financial or business performance, strategies,
expectations and goals.  Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to update
forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to
a number of factors, including: the risk that we may be unable to continue as
a going concern as a result of our inability to raise sufficient capital for
our operational needs; the possibility that we may be delisted from trading on
the Nasdaq Capital Market; the volatility of our common stock; the difficulty
of executing our business strategy in China; our inability to enter into
strategic partnerships for the development, commercialization, manufacturing
and distribution of our proposed product candidate or future candidates; risks
relating to the need for additional capital and the uncertainty of securing
additional funding on favorable terms; declines in actual sales of Thalomid^®
resulting in reduced or no royalty payments; risks associated with our product
candidates; any early-stage products under development; results in preclinical
models are not necessarily indicative of clinical results; uncertainties
relating to preclinical and clinical trials, including delays to the
commencement of such trials; the lack of success in the clinical development
of any of our products; dependence on third parties; and risks relating to the
commercialization, if any, of our proposed products (such as marketing,
safety, regulatory, patent, product liability, supply, competition and other
risks).  Such factors, among others, could have a material adverse effect upon
our business, results of operations and financial condition.  We caution
readers not to place undue reliance on any forward-looking statements, which
only speak as of the date made. Additional information about the factors and
risks that could affect our business, financial condition and results of
operations, are contained in our filings with the U.S. Securities and Exchange
Commission ("SEC"), which are available at www.sec.gov.

COMPANY CONTACT:
Investor Relations
EntreMed, Inc.
investorrelations@entremed.com

SOURCE EntreMed, Inc.

Website: http://www.entremed.com
Contact: EntreMed, Inc., 240.864.2643
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement